Nano-Dry-Melting: A Novel Technology for Manufacturing of Pharmaceutical Amorphous Solid Dispersions

Amorphous solid dispersions (ASD) are one of the most prominent formulation approaches to overcome bioavailability issues that are often presented by new poorly soluble drug candidates. State-of-the art manufacturing techniques include hot melt extrusion and solvent-based methods like spray drying....

Full description

Bibliographic Details
Main Authors: Malin Hermeling, Christoph Nueboldt, Roman Heumann, Werner Hoheisel, Joerg Breitkreutz
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Pharmaceutics
Subjects:
Online Access:https://www.mdpi.com/1999-4923/14/10/2145
_version_ 1797470308533272576
author Malin Hermeling
Christoph Nueboldt
Roman Heumann
Werner Hoheisel
Joerg Breitkreutz
author_facet Malin Hermeling
Christoph Nueboldt
Roman Heumann
Werner Hoheisel
Joerg Breitkreutz
author_sort Malin Hermeling
collection DOAJ
description Amorphous solid dispersions (ASD) are one of the most prominent formulation approaches to overcome bioavailability issues that are often presented by new poorly soluble drug candidates. State-of-the art manufacturing techniques include hot melt extrusion and solvent-based methods like spray drying. The high thermal and mechanical shear stress during hot melt extrusion, or the use of an organic solvent during solvent-based methods, are examples of clear drawbacks for those methods, limiting their applicability for certain systems. In this work a novel process technology is introduced, called Nano-Dry-Melting (NDM), which can provide an alternative option for ASD manufacturing. NDM consists of a comminution step in which the drug is ground to nanosize and a drying step provides a complete amorphization of the system at temperatures below the melting point. Two drug–polymer systems were prepared using NDM with a wet media mill and a spray dryer and analyzed regarding their degree of crystallinity using XRD analysis. Feasibility studies were performed with indomethacin and PVP. Furthermore, a “proof-of-concept” study was conducted with niclosamide. The experiments successfully led to amorphous samples at temperatures of about 50 K below the melting point within seconds of heat exposition. With this novel, solvent-free and therefore “green” production technology it is feasible to manufacture ASDs even with those drug candidates that cannot be processed by conventional process technologies.
first_indexed 2024-03-09T19:35:42Z
format Article
id doaj.art-898fe393673644149ec5309d81e08a41
institution Directory Open Access Journal
issn 1999-4923
language English
last_indexed 2024-03-09T19:35:42Z
publishDate 2022-10-01
publisher MDPI AG
record_format Article
series Pharmaceutics
spelling doaj.art-898fe393673644149ec5309d81e08a412023-11-24T01:56:55ZengMDPI AGPharmaceutics1999-49232022-10-011410214510.3390/pharmaceutics14102145Nano-Dry-Melting: A Novel Technology for Manufacturing of Pharmaceutical Amorphous Solid DispersionsMalin Hermeling0Christoph Nueboldt1Roman Heumann2Werner Hoheisel3Joerg Breitkreutz4INVITE GmbH, 51368 Leverkusen, GermanyINVITE GmbH, 51368 Leverkusen, GermanyBayer AG, 51368 Leverkusen, GermanyINVITE GmbH, 51368 Leverkusen, GermanyInstitute of Pharmaceutics and Biopharmaceutics, Heinrich Heine University Duesseldorf, 40225 Duesseldorf, GermanyAmorphous solid dispersions (ASD) are one of the most prominent formulation approaches to overcome bioavailability issues that are often presented by new poorly soluble drug candidates. State-of-the art manufacturing techniques include hot melt extrusion and solvent-based methods like spray drying. The high thermal and mechanical shear stress during hot melt extrusion, or the use of an organic solvent during solvent-based methods, are examples of clear drawbacks for those methods, limiting their applicability for certain systems. In this work a novel process technology is introduced, called Nano-Dry-Melting (NDM), which can provide an alternative option for ASD manufacturing. NDM consists of a comminution step in which the drug is ground to nanosize and a drying step provides a complete amorphization of the system at temperatures below the melting point. Two drug–polymer systems were prepared using NDM with a wet media mill and a spray dryer and analyzed regarding their degree of crystallinity using XRD analysis. Feasibility studies were performed with indomethacin and PVP. Furthermore, a “proof-of-concept” study was conducted with niclosamide. The experiments successfully led to amorphous samples at temperatures of about 50 K below the melting point within seconds of heat exposition. With this novel, solvent-free and therefore “green” production technology it is feasible to manufacture ASDs even with those drug candidates that cannot be processed by conventional process technologies.https://www.mdpi.com/1999-4923/14/10/2145amorphous solid dispersionamorphizationwet stirred media millingspray dryingnanoparticlesnanocomposition
spellingShingle Malin Hermeling
Christoph Nueboldt
Roman Heumann
Werner Hoheisel
Joerg Breitkreutz
Nano-Dry-Melting: A Novel Technology for Manufacturing of Pharmaceutical Amorphous Solid Dispersions
Pharmaceutics
amorphous solid dispersion
amorphization
wet stirred media milling
spray drying
nanoparticles
nanocomposition
title Nano-Dry-Melting: A Novel Technology for Manufacturing of Pharmaceutical Amorphous Solid Dispersions
title_full Nano-Dry-Melting: A Novel Technology for Manufacturing of Pharmaceutical Amorphous Solid Dispersions
title_fullStr Nano-Dry-Melting: A Novel Technology for Manufacturing of Pharmaceutical Amorphous Solid Dispersions
title_full_unstemmed Nano-Dry-Melting: A Novel Technology for Manufacturing of Pharmaceutical Amorphous Solid Dispersions
title_short Nano-Dry-Melting: A Novel Technology for Manufacturing of Pharmaceutical Amorphous Solid Dispersions
title_sort nano dry melting a novel technology for manufacturing of pharmaceutical amorphous solid dispersions
topic amorphous solid dispersion
amorphization
wet stirred media milling
spray drying
nanoparticles
nanocomposition
url https://www.mdpi.com/1999-4923/14/10/2145
work_keys_str_mv AT malinhermeling nanodrymeltinganoveltechnologyformanufacturingofpharmaceuticalamorphoussoliddispersions
AT christophnueboldt nanodrymeltinganoveltechnologyformanufacturingofpharmaceuticalamorphoussoliddispersions
AT romanheumann nanodrymeltinganoveltechnologyformanufacturingofpharmaceuticalamorphoussoliddispersions
AT wernerhoheisel nanodrymeltinganoveltechnologyformanufacturingofpharmaceuticalamorphoussoliddispersions
AT joergbreitkreutz nanodrymeltinganoveltechnologyformanufacturingofpharmaceuticalamorphoussoliddispersions